[1]	Landoni E., Savoldo B.. Treating hematological malignancies with cell therapy: where are we now?. Expert Opin Biol Ther. 2018; 18(1): 65-75.

[2]	Li S., Yang Z., Shen J., Shan J., Qian C.. Adoptive therapy with CAR redirected T cells for hematological malignancies. Sci China Life Sci. 2016; 59(4): 370-378.

[3]	Maude S.L., Laetsch T.W., Buechner J., Rives S., Boyer M., Bittencourt H., . Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378(5): 439-448.

[4]	Neelapu S.S., Locke F.L., Bartlett N.L., Lekakis L.J., Miklos D.B., Jacobson C.A., . Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26): 2531-2544.

[5]	Zhang E., Gu J., Xu H.. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Mol Cancer. 2018; 17(1): 7.

[6]	Gauthier J., Yakoub-Agha I.. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: clinical data to date, current limitations and perspectives. Curr Res Transl Med. 2017; 65(3): 93-102.

[7]	Geyer M.B., Brentjens R.J.. Review: current clinical applications of chimeric antigen receptor (CAR) modified T cells. Cytotherapy. 2016; 18(11): 1393-1409.

[8]	Oluwole O.O., Davila M.L.. At the bedside: clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies. J Leukoc Biol. 2016; 100(6): 1265-1272.

[9]	Zhang B.L., Qin D.Y., Mo Z.M., Li Y., Wei W., Wang Y.S., . Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors. Sci China Life Sci. 2016; 59(4): 340-348.

[10]	Newick K., O'Brien S., Moon E., Albelda S.M.. CAR T cell therapy for solid tumors. Annu Rev Med. 2017; 68: 139-152.

[11]	Mirzaei H.R., Rodriguez A., Shepphird J., Brown C.E., Badie B.. Chimeric antigen receptors T cell therapy in solid tumor: challenges and clinical applications. Front Immunol. 2017; 8: 1850.

[12]	US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for human somatic cell therapy and gene therapy. Hum Gene Ther. 2001; 12(3): 303-314.

[13]	European Medicines Agency. Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells.

[14]	European Medicines Agency. Guideline on human cell-based medicinal products.

[15]	China Food and Drug Administration. Technical guideline on human cell therapy research and quality control of preparation. Chinese

[16]	China Food and Drug Administration. Technical guideline on cell therapy product research and evaluation (trial). Chinese

[17]	Petricciani J., Hayakawa T., Stacey G., Trouvin J.H., Knezevic I.. Scientific considerations for the regulatory evaluation of cell therapy products. Biologicals. 2017; 50: 20-26.

[18]	Plavsic M.. Q5D: derivation and characterization of cell substrates used for production of biotechnological/biological products. In: editor. ICH quality guidance: an implementation guide. New Jersey: John Wiley & Sons, Inc.; 1998. p. 375-393.

[19]	World Health Organization. Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks.

[20]	The United States Pharmacopeial Convention. Ancillary materials for cell, gene and tissue engineered products. In: The United States pharmacopeia and the national formulary: general chapter <1043>. Rockville: The United States Pharmacopeial Convention; 2012. p. 6850-6858.

[21]	Armstrong A.. Advances in assay technologies for CAR T-cell therapies. BioPharm Int. 2016; 28(2): 32-37.

[22]	Piscopo NJ, Mueller KP, Das A, Hematti P, Murphy WL, Palecek SP, et al. Bioengineering solutions for manufacturing challenges in CAR T cells.Biotechnol J. Epub 2017 Sep 18.

[23]	Gee A.P.. Manufacturing genetically modified T cells for clinical trials. Cancer Gene Ther. 2015; 22(2): 67-71.

[24]	Hollyman D., Stefanski J., Przybylowski M., Bartido S., Borquez-Ojeda O., Taylor C., . Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 2009; 32(2): 169-180.

[25]	Tumaini B., Lee D.W., Lin T., Castiello L., Stroncek D.F., Mackall C., . Simplified process for the production of anti-CD19-CAR-engineered T cells. Cytotherapy. 2013; 15(11): 1406-1415.

[26]	Center for Drug Evaluation of the China Food and Drug Administration. Current considerations for non-clinical research and evaluation of CAR-T products. Chinese

[27]	National Institutes for Food and Drug Control. Notice on the publication of “Considerations for quality control testing and non-clinical research of CAR-T cell therapy products”. Chinese

[28]	Siegler E.L., Wang P.. Preclinical models in chimeric antigen receptor-engineered T-cell therapy. Hum Gene Ther. 2018; 29(5): 534-546.

[29]	Hudecek M., Sommermeyer D., Kosasih P.L., Silva-Benedict A., Liu L., Rader C., . The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015; 3(2): 125-135.

[30]	Cooper L.J., Al-Kadhimi Z., Serrano L.M., Pfeiffer T., Olivares S., Castro A., . Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood. 2005; 105(4): 1622-1631.

[31]	Haso W., Lee D.W., Shah N.N., Stetler-Stevenson M., Yuan C.M., Pastan I.H., . Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013; 121(7): 1165-1174.

[32]	Hudecek M., Lupo-Stanghellini M.T., Kosasih P.L., Sommermeyer D., Jensen M.C., Rader C., . Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 2013; 19(12): 3153-3164.

[33]	Tammana S., Huang X., Wong M., Milone M.C., Ma L., Levine B.L., . 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther. 2010; 21(1): 75-86.

[34]	Fesnak A.D., June C.H., Levine B.L.. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016; 16(9): 566-581.

[35]	Jackson H.J., Rafiq S., Brentjens R.J.. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016; 13(6): 370-383.

[36]	Sadelain M., Brentjens R., Rivière I.. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013; 3(4): 388-398.

[37]	Sommermeyer D., Hudecek M., Kosasih P.L., Gogishvili T., Maloney D.G., Turtle C.J., . Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016; 30(2): 492-500.

[38]	Ghosh A., Smith M., James S.E., Davila M.L., Velardi E., Argyropoulos K.V., . Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med. 2017; 23(2): 242-249.

[39]	Liu L., Sommermeyer D., Cabanov A., Kosasih P., Hill T., Riddell S.R.. Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy. Nat Biotechnol. 2016; 34(4): 430-434.

[40]	Almåsbak H., Walseng E., Kristian A., Myhre M.R., Suso E.M., Munthe L.A., . Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Gene Ther. 2015; 22(5): 391-403.

[41]	Li Y.H., Rao C.M., Zhao Y., Gao K., Yuan L.Y., Han C.M., . Study of requirements for quality control of recombinant adenovirus-mediated human endostatin. Chin J Cancer Biother. 2005; 12(2): 138-142. Chinese

[42]	Li Y.H., Zang Y.C., Yuan L.Y., Shi X.C., Rao C.M., Wang J.Z.. Study on quality control methods and requirements of recombinant plasmid DNA expressing human plasminogen kringle 5. Chin J Pharm Anal. 2008; 28(5): 661-666. Chinese

[43]	Fu Z.H., Gao K., Li Y.H., Li X., Tai L., Wang L., . Analysis on quality of recombinant adeno-associated virus 2 encoding tumor necrosis factor-related apoptosis-induced ligand. Chin J Biologicals. 2015; 28(5): 501-504. Chinese

[44]	Wang X., Rivière I.. Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther. 2015; 22(2): 85-94.

[45]	Singh H., Figliola M.J., Dawson M.J., Olivares S., Zhang L., Yang G., . Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS ONE. 2013; 8(5): e64138.

[46]

Center for Biologics Evaluation and Research [CBER] (United States). Guidance for industry: supplemental guidance on testing for replication-competent retrovirus in retroviral vector based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors. Hum Gene Ther. 2001; 12(3): 315-320.

[47]	Cornetta K., Yao J., Jasti A., Koop S., Douglas M., Hsu D., . Replication-competent lentivirus analysis of clinical grade vector products. Mol Ther. 2011; 19(3): 557-566.

[48]	Long Z., Li L.P., Grooms T., Lockey C., Nader K., Mychkovsky I., . Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells. Hum Gene Ther. 1998; 9(8): 1165-1172.

[49]	Martineau D., Klump W.M., McCormack J.E., DePolo N.J., Kamantigue E., Petrowski M., . Evaluation of PCR and ELISA assays for screening clinical trial subjects for replication-competent retrovirus. Hum Gene Ther. 1997; 8(10): 1231-1241.

[50]	Printz M., Reynolds J., Mento S.J., Jolly D., Kowal K., Sajjadi N.. Recombinant retroviral vector interferes with the detection of amphotropic replication competent retrovirus in standard culture assays. Gene Ther. 1995; 2(2): 143-150.

[51]	Forestell S.P., Dando J.S., Böhnlein E., Rigg R.J.. Improved detection of replication-competent retrovirus. J Virol Methods. 1996; 60(2): 171-178.

[52]	Miller A.D., Bonham L., Alfano J., Kiem H.P., Reynolds T., Wolgamot G.. A novel murine retrovirus identified during testing for helper virus in human gene transfer trials. J Virol. 1996; 70(3): 1804-1809.

[53]	Escarpe P., Zayek N., Chin P., Borellini F., Zufferey R., Veres G., . Development of a sensitive assay for detection of replication-competent recombinant lentivirus in large-scale HIV-based vector preparations. Mol Ther. 2003; 8(2): 332-341.

[54]	Farley D.C., McCloskey L., Thorne B.A., Tareen S.U., Nicolai C.J., Campbell D.J., . Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectors. Mol Ther Methods Clin Dev. 2015; 2: 15017.

[55]	Corre G., Dessainte M., Marteau J.B., Dalle B., Fenard D., Galy A.. “RCL-pooling assay”: a simplified method for the detection of replication-competent lentiviruses in vector batches using sequential pooling. Hum Gene Ther. 2016; 27(2): 202-210.

[56]	Bear A.S., Morgan R.A., Cornetta K., June C.H., Binder-Scholl G., Dudley M.E., . Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?. Mol Ther. 2012; 20(2): 246-249.

[57]	McGarrity G.J., Hoyah G., Winemiller A., Andre K., Stein D., Blick G., . Patient monitoring and follow-up in lentiviral clinical trials. J Gene Med. 2013; 15(2): 78-82.

[58]	Marcucci K.T., Jadlowsky J.K., Hwang W.T., Suhoski-Davis M., Gonzalez V.E., Kulikovskaya I., . Retroviral and lentiviral safety analysis of gene-modified T cell products and infused HIV and oncology patients. Mol Ther. 2018; 26(1): 269-279.

[59]	Cornetta K., Duffy L., Turtle C.J., Jensen M., Forman S., Binder-Scholl G., . Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products. Mol Ther. 2018; 26(1): 280-288.

[60]	Hocquet D., Sauget M., Roussel S., Malugani C., Pouthier F., Morel P., . Validation of an automated blood culture system for sterility testing of cell therapy products. Cytotherapy. 2014; 16(5): 692-698.

[61]	Volokhov D.V., Graham L.J., Brorson K.A., Chizhikov V.E.. Mycoplasma testing of cell substrates and biologics: review of alternative non-microbiological techniques. Mol Cell Probes. 2011; 25(2–3): 69-77.

[62]	Uphoff C.C., Drexler H.G.. Eradication of mycoplasma contaminations from cell cultures. Curr Protoc Mol Biol. 2014; 106: 28.5.1–12

[63]	Skrdlant L.M., Armstrong R.J., Keidaisch B.M., Lorente M.F., DiGiusto D.L.. Detection of replication competent lentivirus using a qPCR assay for VSV-G. Mol Ther Methods Clin Dev. 2017; 8: 1-7.

[64]	Mallet L., Gisonni-Lex L.. Need for new technologies for detection of adventitious agents in vaccines and other biological products. PDA J Pharm Sci Technol. 2014; 68(6): 556-562.

[65]	Mee E.T., Preston M.D., Minor P.D., Schepelmann S., CS533 Study Participants. Development of a candidate reference material for adventitious virus detection in vaccine and biologicals manufacturing by deep sequencing. Vaccine. 2016; 34(17): 2035-2043.

[66]	McClenahan S.D., Uhlenhaut C., Krause P.R.. Evaluation of cells and biological reagents for adventitious agents using degenerate primer PCR and massively parallel sequencing. Vaccine. 2014; 32(52): 7115-7121.

[67]	US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry—potency tests for cellular and gene therapy products.

[68]	Bravery C.A., Carmen J., Fong T., Oprea W., Hoogendoorn K.H., Woda J., . Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry. Cytotherapy. 2013; 15(1): 9-19.

[69]	Xiong W., Chen Y., Kang X., Chen Z., Zheng P., Hsu Y.H., . Immunological synapse predicts effectiveness of chimeric antigen receptor cells. Mol Ther. 2018; 26(4): 963-975.

[70]	Levine B.L., Miskin J., Wonnacott K., Keir C.. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2016; 4: 92-101.

[71]	Revzin A., Maverakis E., Chang H.C.. Biosensors for immune cell analysis—a perspective. Biomicrofluidics. 2012; 6(2): 021301.

[72]	Baradez M.O., Marshall D.. The use of multidimensional image-based analysis to accurately monitor cell growth in 3D bioreactor culture. PLoS ONE. 2011; 6(10): e26104.

[73]	Aghaeepour N., Finak G., Hoos H., Mosmann T.R., Brinkman R., Gottardo R., . Critical assessment of automated flow cytometry data analysis techniques. Nat Methods. 2013; 10(3): 228-238.

[74]	Kuystermans D., Avesh M., Al-Rubeai M.. Online flow cytometry for monitoring apoptosis in mammalian cell cultures as an application for process analytical technology. Cytotechnology. 2016; 68(3): 399-408.

[75]	Locasale J.W., Cantley L.C.. Metabolic flux and the regulation of mammalian cell growth. Cell Metab. 2011; 14(4): 443-451.

[76]	Lipsitz Y.Y., Timmins N.E., Zandstra P.W.. Quality cell therapy manufacturing by design. Nat Biotechnol. 2016; 34(4): 393-400.

[77]	Fesnak A.D., Hanley P.J., Levine B.L.. Considerations in T cell therapy product development for B cell leukemia and lymphoma immunotherapy. Curr Hematol Malig Rep. 2017; 12(4): 335-343.

[78]	Lock D., Mockel-Tenbrinck N., Drechsel K., Barth C., Mauer D., Schaser T., . Automated manufacturing of potent CD20-directed chimeric antigen receptor T cells for clinical use. Hum Gene Ther. 2017; 28(10): 914-925.

[79]	Zhao Y., Stepto H., Schneider C.K.. Organization lentiviral vector standard: toward the production control and standardization of lentivirus-based gene therapy products. Hum Gene Ther Methods. 2017; 28(4): 205-214.

[80]	Wang Y.S., Tian Z.G.. Construction and application of humanized immune system mice. Chin J Immunol. 2016; 32(3): 289-298. Chinese

[81]	Siegler E.L., Wang P.. Preclinical models in chimeric antigen receptor-engineered T cell therapy. Hum Gene Ther. 2018; 29(5): 534-546.

[82]	Cheadle E.J., Hawkins R.E., Batha H., O'Neill A.L., Dovedi S.J., Gilham D.E.. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol. 2010; 184(4): 1885-1896.

[83]	Bonifant C.L., Jackson H.J., Brentjens R.J., Curran K.J.. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016; 3: 16011.